Healthcare costs of patients with cancer stratified by Khorana score risk levels

References

• Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–722.
   PubMed Web of Science ®Google Scholar
• Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4(3):529–535.
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809–815.
   PubMed Web of Science ®Google Scholar
• Cohoon KP, Ransom JE, Leibson CL, et al. Direct medical costs attributable to cancer-associated venous thromboembolism: a population-based longitudinal study. Am J Med. 2016;129(9):1000.e15–1000.25.
   Web of Science ®Google Scholar
• Connolly GC, Dalal M, Lin J, et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer. 2012;78(3):253–258.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Dalal MR, Lin J, et al. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res. 2013;5:101–108.
   PubMedGoogle Scholar
• Lyman GH, Eckert L, Wang Y, et al. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist. 2013;18(12):1321–1329.
   PubMed Web of Science ®Google Scholar
• Shah S, Rubin N, Khorana AA. Economic burden of venous thromboembolism in cancer patients—a comparative analysis between matched patients with cancer with and without a diagnosis of venous thromboembolism. Blood. 2018;132(Supplement 1):366–366.
   Web of Science ®Google Scholar
• Lyman GH, Culakova E, Poniewierski MS, et al. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164(Suppl 1):S112–s8.
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–5382.
   PubMed Web of Science ®Google Scholar
• Cella CA, Di Minno G, Carlomagno C, et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncol. 2017;22(5):601–608.
   Google Scholar
• Douce D, Holmes CE, Cushman M, et al. Enhancing the Khorana score: traditional VTE risk factors are important in predicting long term VTE risk in cancer patients initiating chemotherapy. Blood. 2017;130(Supplement 1):753.
   PubMed Web of Science ®Google Scholar
• Hohl Moinat C, Periard D, Grueber A, et al. Predictors of venous thromboembolic events associated with central venous port insertion in cancer patients. J Oncol. 2014;2014:743181.
   PubMedGoogle Scholar
• Kearney JC, Rossi S, Glinert K, et al. Venous thromboembolism (VTE) and survival in a cancer chemotherapy outpatient clinic: a retrospective chart review validation of a VTE predictive model. Blood. 2009;114(22):2503.
   Web of Science ®Google Scholar
• Khorana AA, Rubens D, Francis CW. Screening high-risk cancer patients for VTE: a prospective observational study. Thromb Res. 2014;134(6):1205–1207.
   PubMed Web of Science ®Google Scholar
• Lustig DB, Rodriguez R, Wells PS. Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis. Thromb Res. 2015;136(6):1099–1102.
   PubMed Web of Science ®Google Scholar
• Mandala M, Clerici M, Corradino I, et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’. Ann Oncol. 2012;23(6):1416–1421.
   PubMed Web of Science ®Google Scholar
• Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466–3473.
   PubMed Web of Science ®Google Scholar
• Parker A, Peterson E, Lee AYY, et al. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer. J Thromb Haemost. 2018;16(7):1321–1326.
   PubMed Web of Science ®Google Scholar
• Patell R, Rybicki L, McCrae KR, et al. Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool. Am J Hematol. 2017;92(6):501–507.
   PubMed Web of Science ®Google Scholar
• Posch F, Riedl J, Reitter EM, et al. Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A multi-state model. Thromb Haemost. 2016;115(04):817–826.
   PubMed Web of Science ®Google Scholar
• Santi RM, Ceccarelli M, Bernocco E, et al. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). Thromb Haemost. 2017;117(8):1615–1621.
   Web of Science ®Google Scholar
• Van Es N, Ventresca M, Zhou Q, et al. The Khorana score for the prediction of venous thromboembolism in patients with solid cancer: an individual patient data meta-analysis. J Thromb Haemost. 2017;18(8):1940–1951.
   Google Scholar
• Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291–292.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Cancer-associated venous thromboembolic disease Version 2.2018 2018 [cited 2018 August 30]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf
   Google Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–728.
   PubMed Web of Science ®Google Scholar
• George D, Agnelli G, Fisher W, et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. Blood. 2011;118(21):206.
   Web of Science ®Google Scholar
• Khorana AA, Francis CW, Kuderer NM, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res. 2017;151:89–95.
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–719.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Culakova E, Lyman GH, et al. A validated risk score for venous thromboembolism is predictive of cancer progression and mortality. Oncologist. 2016;21(7):861–867.
   PubMed Web of Science ®Google Scholar
• Sohal DPS, Kuderer NM, Shepherd FA, et al. Clinical predictors of early mortality in colorectal cancer patients undergoing chemotherapy: results from a global prospective cohort study. JNCI Cancer Spectrum. 2017;1(1):pkx009.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Poniewierski MS, Culakova E, et al. Predictors of venous thromboembolism and early mortality in lung cancer: results from a global prospective study (CANTARISK). Oncol. 2018;23(2):247–255.
   Google Scholar
• Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009;29(8):943–953.
   PubMed Web of Science ®Google Scholar
• Cancer Research Network. Cancer Therapy Look-up Tables [cited 2019 August 27]. Available from: http://www.hcsrn.org/crn/en/RESEARCH/LookupTables/
   Google Scholar
• Elixhauser A, Steiner C, Kruzikas D. Comorbidity software documentation. Rockville, MD: Agency for Healthcare Research and Quality; 2004.
   Google Scholar
• Gade IL, Braekkan SK, Naess IA, et al. The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian thrombosis and cancer (STAC) cohort. J Thromb Haemost. 2017;15(8):1567–1575.
   PubMed Web of Science ®Google Scholar
• Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–377.
   PubMed Web of Science ®Google Scholar
• Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–3897.
   PubMed Web of Science ®Google Scholar
• Holland JC, Andersen B, Breitbart WS, et al. Distress management. J Natl Compr Canc Netw. 2013;11(2):190–209.
   PubMed Web of Science ®Google Scholar
• Rosner MH, Perazella MA. Acute kidney injury in patients with cancer. N Engl J Med. 2017;376(18):1770–1781.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, McCrae K, et al. Cancer associated thrombosis and mortality in patients with cancer stratified by Khorana score risk levels. Cancer Med. 2020;9(21):8062–8073.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Vadhan-Raj S, Kuderer NM, et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. Rationale and design of the CASSINI trial. Thromb Haemost. 2017;117(11):2135–2145.
   PubMed Web of Science ®Google Scholar
• Kimpton M, Wells PS, Carrier M. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: rational and design of the AVERT trial. Thromb Res. 2018;164(Suppl 1):S124–S9.
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2019:JCO1901461.
   PubMed Web of Science ®Google Scholar
• Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2019;17(10):1772–1778.
   PubMed Web of Science ®Google Scholar
• Streiff MB, Holmstrom B, Angelini D, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw. 2018;16(11):1289–1303.
   PubMed Web of Science ®Google Scholar